Fresenius stock trades around 45 euros as recent 2026 earnings support guidance

Published on 09/13/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock is trading near 45.00 EUR on Xetra as of September 11, 2026, supported by its latest quarterly figures and confirmed 2026 guidance. Investors also watch the valuation in the multi-billion-euro range compared with its 52-week band.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius SE & Co. KGaA stock (ISIN DE0005785604) is trading around 45.00 EUR on Xetra as of September 11, 2026, leaving the healthcare group valued in the multi-billion-euro range and positioning the shares as a defensive play for investors.

Recent earnings and 2026 guidance

According to Ad-hoc-news, Fresenius reported its most recent quarterly figures for fiscal year 2026 within the last months, with revenue for that quarter in the billions of euros and a positive operating result that underpins the case for the stock.

In that latest quarter of fiscal year 2026, Fresenius generated higher revenue compared with the same period a year earlier, with growth clearly in the single- to low-double-digit percent range, while earnings before interest and taxes also improved versus the prior-year quarter, demonstrating a tangible year-on-year uplift in both top line and operating profitability.Ad-hoc-news

In addition, the company confirmed its guidance for fiscal year 2026 in this reporting package, targeting revenue growth in the mid-single-digit percent range and a further improvement in profitability compared with fiscal year 2025, which gives investors a quantified framework for expected performance over the current year.Ad-hoc-news

Stock performance and valuation band

Fresenius stock most recently changed hands around the mid-40-euro level on Xetra on September 11, 2026, keeping the price clearly above the lower end of its 52-week trading range and below the upper end of that band, which indicates that the shares trade in the middle of their recent performance corridor rather than at an extreme high or low.Ad-hoc-news

The same report cites a price of 45.00 EUR as of September 11, 2026 and a market capitalization of 25,000,000,000 EUR as of that date, which places Fresenius firmly in the large-cap bracket within the European healthcare sector and reflects the market’s perception of its diversified operations in hospitals, medical services and related activities.Ad-hoc-news

Additional trading data from Xetra-oriented portals show Fresenius shares quoted around 47.05 EUR with a very modest daily move of minus 0.23 percent in the latest session, while the weekly change stood close to plus 0.21 percent and the stock has gained around 40.95 percent over the last twelve months, illustrating both short-term stability and a strong longer-term recovery for the shares.TradingView

Technical signals and investor perspective

SAMM Daily

For investors, the combination of improving revenue and EBIT in the latest quarter of fiscal year 2026, the confirmed mid-single-digit revenue growth guidance for the full year 2026 and the fact that the shares trade in the middle of their 52-week range while still showing a roughly 40 percent gain over the last twelve months creates a picture of a healthcare stock that has already rerated but still hinges on the execution of its guidance.

Fresenius stock price as of last trading day

On Xetra, Fresenius stock closed at 45.00 EUR on September 11, 2026, based on the most recent completed trading day data, with the price situated well within its 52-week trading band and a market capitalization of 25,000,000,000 EUR as of that date.